We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Johnson & Johnson (JNJ) Outperforms Broader Market: What You Need to Know
Read MoreHide Full Article
In the latest close session, Johnson & Johnson (JNJ - Free Report) was up +1.05% at $231.73. The stock's change was more than the S&P 500's daily gain of 0.17%. On the other hand, the Dow registered a gain of 0.55%, and the technology-centric Nasdaq increased by 0.09%.
Coming into today, shares of the world's biggest maker of health care products had gained 1.42% in the past month. In that same time, the Medical sector lost 1.33%, while the S&P 500 gained 4.59%.
The upcoming earnings release of Johnson & Johnson will be of great interest to investors. In that report, analysts expect Johnson & Johnson to post earnings of $2.83 per share. This would mark year-over-year growth of 2.17%. Meanwhile, our latest consensus estimate is calling for revenue of $25.04 billion, up 5.46% from the prior-year quarter.
In terms of the entire fiscal year, the Zacks Consensus Estimates predict earnings of $11.57 per share and a revenue of $100.8 billion, indicating changes of +7.23% and +7.02%, respectively, from the former year.
Investors might also notice recent changes to analyst estimates for Johnson & Johnson. These latest adjustments often mirror the shifting dynamics of short-term business patterns. Therefore, positive revisions in estimates convey analysts' confidence in the business performance and profit potential.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. To take advantage of this, we've established the Zacks Rank, an exclusive model that considers these estimated changes and delivers an operational rating system.
The Zacks Rank system, spanning from #1 (Strong Buy) to #5 (Strong Sell), boasts an impressive track record of outperformance, audited externally, with #1 ranked stocks yielding an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has shifted 0.02% upward. At present, Johnson & Johnson boasts a Zacks Rank of #3 (Hold).
Digging into valuation, Johnson & Johnson currently has a Forward P/E ratio of 19.82. This valuation marks a premium compared to its industry average Forward P/E of 14.85.
We can additionally observe that JNJ currently boasts a PEG ratio of 2.25. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. JNJ's industry had an average PEG ratio of 2.54 as of yesterday's close.
The Large Cap Pharmaceuticals industry is part of the Medical sector. At present, this industry carries a Zacks Industry Rank of 71, placing it within the top 30% of over 250 industries.
The Zacks Industry Rank assesses the strength of our separate industry groups by calculating the average Zacks Rank of the individual stocks contained within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Remember to apply Zacks.com to follow these and more stock-moving metrics during the upcoming trading sessions.
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
Johnson & Johnson (JNJ) Outperforms Broader Market: What You Need to Know
In the latest close session, Johnson & Johnson (JNJ - Free Report) was up +1.05% at $231.73. The stock's change was more than the S&P 500's daily gain of 0.17%. On the other hand, the Dow registered a gain of 0.55%, and the technology-centric Nasdaq increased by 0.09%.
Coming into today, shares of the world's biggest maker of health care products had gained 1.42% in the past month. In that same time, the Medical sector lost 1.33%, while the S&P 500 gained 4.59%.
The upcoming earnings release of Johnson & Johnson will be of great interest to investors. In that report, analysts expect Johnson & Johnson to post earnings of $2.83 per share. This would mark year-over-year growth of 2.17%. Meanwhile, our latest consensus estimate is calling for revenue of $25.04 billion, up 5.46% from the prior-year quarter.
In terms of the entire fiscal year, the Zacks Consensus Estimates predict earnings of $11.57 per share and a revenue of $100.8 billion, indicating changes of +7.23% and +7.02%, respectively, from the former year.
Investors might also notice recent changes to analyst estimates for Johnson & Johnson. These latest adjustments often mirror the shifting dynamics of short-term business patterns. Therefore, positive revisions in estimates convey analysts' confidence in the business performance and profit potential.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. To take advantage of this, we've established the Zacks Rank, an exclusive model that considers these estimated changes and delivers an operational rating system.
The Zacks Rank system, spanning from #1 (Strong Buy) to #5 (Strong Sell), boasts an impressive track record of outperformance, audited externally, with #1 ranked stocks yielding an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has shifted 0.02% upward. At present, Johnson & Johnson boasts a Zacks Rank of #3 (Hold).
Digging into valuation, Johnson & Johnson currently has a Forward P/E ratio of 19.82. This valuation marks a premium compared to its industry average Forward P/E of 14.85.
We can additionally observe that JNJ currently boasts a PEG ratio of 2.25. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. JNJ's industry had an average PEG ratio of 2.54 as of yesterday's close.
The Large Cap Pharmaceuticals industry is part of the Medical sector. At present, this industry carries a Zacks Industry Rank of 71, placing it within the top 30% of over 250 industries.
The Zacks Industry Rank assesses the strength of our separate industry groups by calculating the average Zacks Rank of the individual stocks contained within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Remember to apply Zacks.com to follow these and more stock-moving metrics during the upcoming trading sessions.